Paul Nunzio De Santis

Dr. Paul De Santis, PharmD joined Molekule Consulting after spending 4 years as a GLG special council member in Immuno-Oncology and Cell Therapy consulting for several of the largest global Private Equity and Hedge Funds with more than $10B in assets under management. During this time clients leveraged his depth of expertise on commercial dynamics operating within the Cell and Gene Therapy landscape to perform deep-dive addressable market analyses and leveraged his clinical expertise to understand an asset's probability of regulatory and commercial success in support of valuation analysis.

In addition, he supported pre-commercial planning for several CAR T companies leveraging these skillsets to develop commercialization strategies that can maximize patient access to autologous cell therapies. Dr. De Santis provides deep expertise across the hematology/oncology and immuno-oncology landscapes and this is supported by 4 years of clinical training and 5 years of translational oncology research.